Drug Profile
JVC 001
Alternative Names: JVC-001; Measles-mumps-and-rubella-virus-vaccine-Daiichi; MMR-vaccine-Daiichi-Sankyo; VN 0102Latest Information Update: 22 Dec 2021
Price :
$50
*
At a glance
- Originator Japan Vaccine
- Class Measles vaccines; Mumps vaccines; Rubella vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Measles; Mumps; Rubella
Most Recent Events
- 26 Nov 2021 Daiichi Sankyo completes a phase III trial in Mumps, Measles and Rubella (Prevention, In infants) in Japan (SC) (JapicCTI-205118)
- 11 Aug 2020 Daiichi Sankyo completes a phase III trial in Mumps, Measles and Rubella (Prevention, In infants) in Japan (SC) (JapicCTI-205117)
- 01 Feb 2020 Daiichi Sankyo initiates phase III trial in Mumps, Measles and Rubella (Prevention, In infants) in Japan (SC) (JapicCTI-205117)